The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharma: anti-sense oligonucleotides. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Anti-sense oligonucleotides is a key innovation area in genomics
Anti-sense oligonucleotides are synthetic, single-stranded strands of DNA or RNA sequences that can bind to complementary target RNA sequences, leading to the degradation or inhibition of translation of the target RNA. By targeting specific RNA sequences, anti-sense oligonucleotides can modulate gene expression and have potential therapeutic applications in treating various diseases.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 285+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-sense oligonucleotides.
Key players in anti-sense oligonucleotides – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Ionis Pharmaceuticals (Ionis) is one of the leading patent filers in anti-sense oligonucleotides. Formerly known as ISIS Pharmaceuticals, Ionis focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical development. It develops products based on its proprietary antisense technology. The company partners with other pharmaceutical companies to develop a range of products in different therapeutic areas. F. Hoffmann-La Roche and Alnylam Pharmaceuticals are some of the other key patent filers in anti-sense oligonucleotides.
In terms of application diversity, AptaBio Therapeutics leads the pack, while Johnson & Johnson and EdiGene stood in the second and third positions, respectively.
By means of geographic reach, the Novartis held the top position followed by Pfizer and Dynavax Technologies.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
